GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Molecular Templates
Matterport is a leader in creating "digital twins" of physical spaces. Its stock price is a story of its rise during the metaverse hype and subsequent decline. The chart reflects the company's search for a sustainable business model and widespread adoption of the technology.
Share prices of companies in the market segment - Oncology platforms
Molecular Templates is an oncology company developing a platform for creating targeted toxins that deliver powerful poisons directly to cancer cells. We've categorized it as an "Oncology Platform." The chart below shows how the market values innovative approaches to cancer treatment.
Broad Market Index - GURU.Markets
Molecular Templates is an oncology company developing a new class of drugs that can penetrate cells and destroy them from the inside. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Molecular Templates shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MTEM - Daily change in the company's share price Molecular Templates
For Molecular Templates, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Molecular Templates is developing a new generation of immunotoxins for cancer treatment. Oncology, especially in the early stages of development, is a highly volatile sector. The chart below shows the average fluctuations in this industry, providing context for assessing the risks of MTEM.
Daily change in the price of a broad market stock, index - GURU.Markets
Molecular Templates is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Molecular Templates
Molecular Templates' year-to-date performance is the story of its unique platform for creating next-generation toxins. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which can overcome resistance to other treatments, will be a breakthrough in oncology.
Annual dynamics of market capitalization of the market segment - Oncology platforms
As an early-stage biotech company, Molecular Templates is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its platform for developing targeted cancer drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Molecular Templates, a biotech company developing a new generation of targeted cancer therapy, is a high-risk scientific project. Its annual market capitalization dynamics, compared to the market, reflect investors' faith in its unique technological platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Molecular Templates
Molecular Templates is an oncology company with a unique platform. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its technology are the primary driver.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
This chart reflects the dynamics of the volatile biotech sector. For Molecular Templates, an oncology company, it's the backdrop. Its movements illustrate how the successes and failures of clinical trials for its unique platform influence investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Molecular Templates is a biotech company developing a new generation of immunotoxins for cancer treatment. This is a high-risk area. The overall market chart provides only background information, while MTEM's performance is driven by news about clinical trials, which can trigger sharp movements counter to any market trend, as is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Molecular Templates
The weekly performance of Molecular Templates, a biopharmaceutical company, reflects the development of a new class of cancer drugs. Share prices are responding to clinical trial data from their platform, which is designed to deliver toxins directly to cancer cells.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Molecular Templates is developing next-generation oncology drugs (ETBs). This chart compares its volatile, data-driven performance with the broader sector to understand how investors believe its unique technology platform is superior to other approaches.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Molecular Templates is a biotech company whose value depends on clinical trial results. Shares in this sector often move independently of the market. This chart will help you understand: do MTEM shares follow the broader market or are news about its developments driving a completely independent trajectory?
Market capitalization of the company, segment and market as a whole
MTEM - Market capitalization of the company Molecular Templates
Molecular Templates' market capitalization tells the story of developing a new class of oncology drugs (ETBs) that use toxins to kill cancer cells. Its volatile price chart tells a story of scientific potential and clinical setbacks that forced the company to rethink its strategy.
MTEM - Share of the company's market capitalization Molecular Templates within the market segment - Oncology platforms
Molecular Templates is developing a new generation of oncology drugs. The company's share of its segment's market capitalization essentially represents investors' bet on the success of its unique technological platform. The chart illustrates how its weight changes based on clinical trial news.
Market capitalization of the market segment - Oncology platforms
Molecular Templates is a biotech company developing a new generation of targeted cancer therapies. The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which the company is trying to prove the effectiveness of its unique scientific platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
Molecular Templates is developing a new class of oncology drugs called "engineered toxin bodies." Its market cap reflects its unique scientific platform. Its volatility on the overall chart reflects how the market assesses the risks and potential of completely new approaches to cancer treatment.
Book value capitalization of the company, segment and market as a whole
MTEM - Book value capitalization of the company Molecular Templates
Molecular Templates' balance sheet consists of its capital and patents for a unique platform for creating targeted toxins that selectively destroy cancer cells. This is a real, scientific foundation for a new approach in oncology. How has this innovative, yet risky, biotech asset evolved? The chart below shows its dynamics.
MTEM - Share of the company's book capitalization Molecular Templates within the market segment - Oncology platforms
Molecular Templates is developing next-generation oncology drugs (ETB), which requires unique biotech laboratories. The chart shows the share of these tangible assets, reflecting the physical foundation of its innovative therapeutic platform.
Market segment balance sheet capitalization - Oncology platforms
Molecular Templates, a biopharmaceutical company developing a new generation of immunotoxins, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that breakthrough research requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Molecular Templates' balance sheet is its unique ETB scientific platform for developing a new class of anti-cancer drugs. The company's assets include its intellectual capital, patents, and preclinical data. The chart below shows how this science-intensive R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Molecular Templates
Molecular Templates is developing a unique oncology platform. Its balance sheet represents the value of its research. Its market capitalization represents the bet that its technology will prove effective in the fight against cancer. The chart shows how high investors' hopes are for a scientific breakthrough, potentially worth billions.
Market to book capitalization ratio in a market segment - Oncology platforms
Molecular Templates is developing a new generation of anti-cancer drugs capable of penetrating tumor cells. Like many research-stage biotech companies, its valuation is based entirely on the potential of its unique scientific platform, not its tangible assets.
Market to book capitalization ratio for the market as a whole
Molecular Templates develops oncology drugs, and its value is determined by its portfolio of developments and patents. These are intangible assets that the market values based on future success. This chart shows how the premium for biotech innovation differs from the average valuation of the overall stock market.
Debts of the company, segment and market as a whole
MTEM - Company debts Molecular Templates
Molecular Templates, a biotech company developing a unique platform for creating targeted oncology drugs, is using capital to fund its preclinical and early clinical trials. This chart shows how the company is raising high-risk investments to validate its innovative but complex scientific concept.
Market segment debts - Oncology platforms
Molecular Templates is a biotech company developing a new generation of targeted oncology drugs. During clinical development, such companies almost always avoid debt due to the high risks. This chart demonstrates that the company, like its peers in the sector, relies exclusively on equity capital to fund its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Molecular Templates
Molecular Templates is a biotech company developing a platform for creating targeted oncology drugs. This chart shows the extent to which the company finances its cutting-edge but risky research with debt. It is an indicator of its financial risk in the long and capital-intensive process of developing a new class of drugs.
Market segment debt to market segment book capitalization - Oncology platforms
Molecular Templates is developing a new class of cancer drugs (ETBs) that use a toxin to destroy tumor cells. This is an innovative but risky technology. The chart shows how aggressively the biotech sector uses debt for R&D, providing context for assessing Molecular Templates' capital-intensive strategy and risks.
Debt to book value of all companies in the market
Molecular Templates is developing a new generation of oncology drugs, a capital-intensive process with high risks and a long R&D cycle. This chart, reflecting the overall debt burden in the market, provides context. It helps assess how the company finances its cutting-edge scientific platforms and how its debt policy compares to the biotech industry.
P/E of the company, segment and market as a whole
P/E - Molecular Templates
Molecular Templates is developing a new generation of immunotoxins, called ETBs, for cancer treatment. This chart shows the market value of its unique technology platform. The valuation is based not on current profits, but on clinical trial results and the potential of this technology to create effective anticancer drugs.
P/E of the market segment - Oncology platforms
This chart for biotech companies serves as a benchmark for Molecular Templates. It reflects overall high valuations based on breakthrough hopes. Comparisons with this chart help us understand whether Molecular Templates' unique platform for creating cancer-targeted toxins is considered more or less promising than dozens of other oncology biotechs.
P/E of the market as a whole
Molecular Templates is a biotech company developing a new class of targeted cancer therapies. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Molecular Templates's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Molecular Templates
For Molecular Templates, a biopharmaceutical company with a unique platform for creating targeted toxins for cancer treatment, this chart demonstrates market expectations for its clinical developments. It reflects investor confidence in the potential of this innovative technology and its future commercial success.
%20P%2FE%20Molecular%20Templates&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Molecular-Templates&v=1772610605741 "Chart of the company's future (projected) P/E Molecular Templates")
Future (projected) P/E of the market segment - Oncology platforms
Molecular Templates is developing a new generation of immunotoxins called ETB (Engineered Toxin Bodies) for the targeted destruction of cancer cells. This is an innovative but risky oncology platform. The chart shows forecasts for the oncology sector, allowing us to compare market confidence in Molecular Templates' technology with expectations for other biotech approaches.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772610605863 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Molecular Templates, Inc. is a biotech company developing a new class of targeted cancer therapies. This is cutting-edge science, and the company's valuation is a bet on the success of its platform. This chart shows how willing investors are to fund fundamental oncology research with a long-term horizon.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772610605912 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Molecular Templates
Molecular Templates is developing a unique platform for the creation of targeted oncology drugs (ETBs). Currently in the clinical stage, the company has no commercial revenue. This chart shows the financial implications of developing a breakthrough technology that could offer a new way to fight cancer, but requires significant investment.
Profit of companies in the market segment - Oncology platforms
Molecular Templates is developing a new generation of targeted cancer therapies called engineered toxin bodies (ETBs). This chart, which reflects profitability in the oncology sector, shows how science is searching for breakthrough approaches. Their technology uses a toxin to destroy cancer cells, and its success depends on clinical trial results and the ability to minimize side effects.
Overall market profit
Molecular Templates is developing a new generation of targeted cancer therapy called engineered toxin bodies. This is an innovative but risky technology. Funding for such breakthrough research depends on investors' risk appetite. Growing overall market returns, as shown in this chart, are typically accompanied by increased investment in advanced biotech platforms.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Molecular Templates
Molecular Templates is developing a new generation of targeted oncology drugs, known as engineered toxin bodies (ETBs), to destroy cancer cells. This graph represents analysts' expectations for the success of clinical trials of this innovative platform, which is a bet on a new approach to cancer treatment.
%20profit%20of%20the%20company%20Molecular%20Templates&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Molecular-Templates&v=1772610606022 "Graph of future (projected) profit of the company Molecular Templates")
Future (predicted) profit of companies in the market segment - Oncology platforms
Molecular Templates is a biopharmaceutical company developing a new generation of targeted oncology therapies called engineered toxin bodies (ETBs). Its value lies in the potential of its innovative platform. This chart for the oncology sector demonstrates the overall market belief that new technologies can lead to more effective and safer drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772610606061 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Molecular Templates is developing a new generation of oncology drugs. The company's success depends on its scientific platform. The overall profit forecast shown in this chart influences the overall risk appetite of investors and the willingness of large pharmaceutical companies to invest in innovative, yet unproven, technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772610606069 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Molecular Templates
Molecular Templates is a biotech company developing a new generation of targeted oncology drugs. Since the company is in the research stage, this chart is crucial. It shows how investors view its unique scientific platform and potential future revenue from partnerships or its own products.
P/S market segment - Oncology platforms
Molecular Templates is developing a new generation of targeted oncology drugs known as engineered toxin bodies. The company's valuation is based on the potential of this unique therapeutic platform. This chart reflects the average valuation in the biotech industry, helping investors understand how expectations for Molecular Templates' innovative technology align with trends.
P/S of the market as a whole
Molecular Templates is a biotech company developing a new generation of immunotoxins (ETBs) for cancer treatment. This technology aims to destroy cancer cells with minimal damage to healthy cells. This chart, which reflects revenue estimates for traditional companies, highlights that MTEM's valuation is a bet on its unique scientific platform and future clinical success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Molecular Templates
Molecular Templates is a biotech company developing a new class of targeted cancer therapies called ETB (Engineered Toxin Bodies). It's an innovative but risky technology. This chart reflects investor hopes that the company's scientific platform will prove effective in the clinic and lead to the creation of breakthrough drugs.
%20P%2FS%20Molecular%20Templates&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Molecular-Templates&v=1772610606205 "The graph of the company's future (projected) P/S Molecular Templates")
Future (projected) P/S of the market segment - Oncology platforms
Molecular Templates, Inc. is a biopharmaceutical company developing a platform for the creation of a new class of targeted oncology drugs called engineered toxin bodies (ETBs). This chart reflects average revenue expectations in the oncology sector. It provides an indication of how highly the market values Molecular Templates' innovative approach to cancer treatment.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772610606382 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Molecular Templates is developing a new generation of targeted oncology drugs, called engineered toxin bodies, which deliver a potent toxin directly to cancer cells. This indicator reflects the collective market expectation. The company's innovative approach may offer new treatment options for difficult-to-treat tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772610606501 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Molecular Templates
This chart illustrates the revenue of Molecular Templates, a clinical-stage biotech developing a new generation of oncology drugs. Its revenue is generated through collaboration fees with pharmaceutical partners. The trend reflects research successes and achievement of key development milestones, not sales.
Sales of companies in the market segment - Oncology platforms
Molecular Templates is developing a new generation of oncology drugs called "engineered toxin bodies" (ETBs), which deliver toxins directly to cancer cells. This graph reflects the growth of the targeted therapy market. The company's innovative platform could lead to breakthrough treatments, expanding therapeutic options across all oncology fields.
Overall market sales
Molecular Templates is a biotech company developing a new generation of oncology drugs. Its development depends on successful clinical trials and partnerships. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Molecular Templates
Molecular Templates is developing a new generation of targeted oncology drugs. Since the company is in clinical trials, this chart reflects future revenue potential. It illustrates analysts' confidence in the success of its unique therapeutic platform.
%20sales%20of%20the%20company%20Molecular%20Templates&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Molecular-Templates&v=1772610606660 "Schedule of future (projected) sales of the company Molecular Templates")
Future (projected) sales of companies in the market segment - Oncology platforms
Molecular Templates is developing a new generation of targeted oncology drugs, called engineered toxin bodies (ETBs), that can destroy cancer cells. This graph shows the forecast for the entire oncology market, where innovative platforms like MTEM's could open new avenues for treating difficult-to-treat tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772610606681 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Molecular Templates is a clinical-stage biotech company developing a new generation of immunotoxins for cancer treatment. Its valuation depends on the success of its unique scientific platform. This graph, reflecting investors' risk appetite, impacts the availability of capital for funding innovative, yet unproven, approaches in oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772610606703 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Molecular Templates
Molecular Templates is developing a new generation of targeted oncology drugs based on its unique platform. Currently in clinical trials, the company is fully focused on science. This chart shows its operating losses—the necessary investments in developing innovative treatments that could transform the fight against cancer.
Market segment marginality - Oncology platforms
Molecular Templates is a biotechnology company developing a unique platform for creating targeted anti-cancer drugs called "engineered toxin bodies." At the clinical stage, profitability is the goal. This graph reflects R&D investments. Investors analyze it to assess the potential of this innovative technology.
Market marginality as a whole
Molecular Templates is a biotech company developing a new class of drugs called "engineered toxin bodies" for the treatment of cancer. Their platform aims to destroy cancer cells in a unique way. This overall profitability curve is irrelevant to them. Their valuation depends solely on the potential of their scientific platform and success in clinical development.
Employees in the company, segment and market as a whole
Number of employees in the company Molecular Templates
Molecular Templates is a biotechnology company developing a new generation of targeted cancer therapies. Its team consists primarily of scientists working on a unique protein platform. This chart reflects the intensity of its research and development activities and the number of programs in development.
Share of the company's employees Molecular Templates within the market segment - Oncology platforms
Molecular Templates is developing a new generation of anti-cancer drugs based on its proprietary "engineered toxin body" platform. This chart shows the share of unique scientific talent the company attracts in this innovative field of biotechnology. This growth reflects the expansion of its research platform and progress in creating next-generation drugs.
Number of employees in the market segment - Oncology platforms
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company developing a new generation of immunotoxins for cancer treatment. This chart shows the employment dynamics in the oncology platform sector. The growing number of scientists here reflects investor confidence in the potential of this technology, which could offer a new mechanism for destroying cancer cells with high precision.
Number of employees in the market as a whole
Molecular Templates is a biotech company developing a platform for creating targeted oncology drugs. Its development requires significant investment. General economic stability, illustrated by this chart, influences investor risk appetite and the availability of capital to fund long-term, breakthrough research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Molecular Templates (MTEM)
Molecular Templates is a biotech company developing an innovative platform (ETB) for targeted drug delivery to cancer cells. The company's value depends almost entirely on the success of its R&D. This chart demonstrates how the market values their unique scientific platform and team of scientists. The extremely high market capitalization per employee here suggests that the market is pricing in a future blockbuster, not current revenue.
%20of%20the%20company%20Molecular%20Templates%20(MTEM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Molecular-Templates-MTEM&v=1772610607112 "Chart of market capitalization per employee (in thousands of dollars) of the company Molecular Templates (MTEM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Molecular Templates is developing a new generation of oncology drugs known as engineered toxin bodies. Its valuation is based on its unique scientific platform and development potential. This chart demonstrates the high valuation of its cutting-edge technologies and intellectual property, based on its small but highly qualified team of scientists.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772610607125 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Molecular Templates is a biopharmaceutical company developing a new class of targeted oncology drugs (ETBs). The chart illustrates the valuation of their unique scientific platform. It shows how the market views their innovative approach to cancer cell destruction, which is being developed by a small but highly specialized team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772610607172 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Molecular Templates (MTEM)
Molecular Templates is a clinical-stage biotech company developing a unique platform of "engineered toxin bodies" (ETBs) to destroy cancer cells. This is R&D. This chart shows the company's capital burn: the amount of capital the company spends on each scientist trying to prove the efficacy and safety of their innovative technology.
%20Chart%20Molecular%20Templates%20(MTEM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Molecular-Templates-MTEM&v=1772610607245 "Company Profit Per Employee (in thousands of dollars) Chart Molecular Templates (MTEM)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Molecular Templates is a clinical-stage biotechnology company developing a unique "engineered toxin body" (ETB) platform for cancer treatment. This loss per employee reflects the high cost of R&D and clinical trials to advance this new technology.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772610607277 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Molecular Templates (MTEM) is a clinical-stage biotech company developing a novel platform (ETB) for delivering toxins to cancer cells. This is an R&D business. The company is not profitable. This chart shows the capital burn rate: the operating loss per team of scientists developing this breakthrough technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772610607302 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Molecular Templates (MTEM)
Molecular Templates is developing a new generation of oncology drugs known as engineered toxin bodies. This chart reflects the progress of commercializing its unique scientific platform. Revenue growth at this stage is likely due to milestone payments from pharmaceutical industry partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Molecular-Templates-MTEM&v=1772610607314 "Sales chart per company employee Molecular Templates (MTEM)")
Sales per employee in the market segment - Oncology platforms
Molecular Templates is developing an innovative "engineered toxin body" (ETB) platform for delivering poisons directly to cancer cells. This graph shows how productive their research team is. It measures revenue (usually from partnerships with big pharma) per researcher, reflecting the value of their R&D platform in the segment.
Sales per employee for the market as a whole
Molecular Templates (MTEM) is a biotech company developing a novel "ETB" (Engineered Toxin Bodies) platform for cancer treatment. The company is in the clinical stage. This graph illustrates a typical R&D situation: the company has no commercial revenue, and its entire scientific and research staff is focused on technology development, consuming investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company Molecular Templates (MTEM)
Molecular Templates is a biotech company developing a new platform for delivering drugs to cancer cells. This chart shows bearish sentiment. Investors shorting the stock are betting that this cutting-edge but unproven technology will prove unsafe or ineffective in human clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Molecular-Templates-MTEM&v=1772610607405 "Short Shares Chart for the Company Molecular Templates (MTEM)")
Shares shorted by market segment - Oncology platforms
Molecular Templates (MTEM) is a biopharmaceutical company developing an innovative platform for the creation of targeted oncology drugs (ETBs). These are high-risk scientific developments. This chart reflects the cumulative volume of short bets across the entire biotech sector focused on platform-based research in oncology. It highlights the overall market skepticism regarding the commercial viability of these technologies.
Shares shorted by the overall market
Molecular Templates (MTEM) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like MTEM in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Molecular Templates (MTEM)
This chart for Molecular Templates is an indicator of faith in their oncology platform, ETB. The company develops "toxins" that target cancer cells. "Overheating" (above 70) occurs due to positive preclinical data. Failures in human trials (toxicity issues) and high cash burn lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Molecular-Templates-MTEM&v=1772610607523 "RSI 14 indicator chart for the company's stock Molecular Templates (MTEM)")
RSI 14 Market Segment - Oncology platforms
Molecular Templates (MTEM) is a biotech company developing "smart toxins" (ETBs). These are drugs that penetrate cancer cells and destroy them from the inside. This chart measures the overall sentiment in the oncology sector. It helps distinguish the success of MTEM technology from the overall "overheating" or "overselling" of the biotech sector.
RSI 14 for the overall market
For Molecular Templates, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MTEM (Molecular Templates)
Molecular Templates (MTEM) is a biotech company developing a unique R&D platform (ETB) that uses Shigella toxin to deliver a payload and destroy cancer cells. This chart shows the speculative average 12-month price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MTEM-Molecular-Templates&v=1772610607616 "A chart showing analyst consensus forecasts for the expected stock price. MTEM (Molecular Templates)")
The difference between the consensus estimate and the actual stock price MTEM (Molecular Templates)
Molecular Templates (MTEM) is a biotech company developing "immunotoxins" (ETBs)—a technology that delivers poison *inside* cancer cells. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex yet powerful R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MTEM-Molecular-Templates&v=1772610607662 "A chart showing the difference between the consensus forecast and the actual stock price. MTEM (Molecular Templates)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Molecular Templates (MTEM) is developing "Engineered Toxin Bodies"—a new platform that delivers a potent "toxin" directly to cancer cells, acting as a biological Trojan horse. This chart reflects the collective opinion of the entire "oncology R&D" sector. It shows whether experts believe in funding new, high-risk platforms.
Analysts' consensus forecast for the overall market share price
Molecular Templates is a biotech company developing a platform (ETB) for creating "toxins" that specifically destroy cancer cells. This chart shows the overall "risk appetite" in the market. For MTEM, a clinical-stage company, overall market optimism (the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Molecular Templates
Molecular Templates (MTEM) is a biotech R&D company (oncology). Their signature feature is their R&D platform, ETB (Engineered Toxin Bodies): a new class of drugs that attach a deadly toxin (from bacteria) to a targeting device to deliver the poison directly to cancer cells. This chart is a pure R&D barometer of faith/fear. It reflects not sales, but the market's speculative valuation of their (futuristic) science.
AKIMA Market Segment Index - Oncology platforms
Molecular Templates (MTEM) is an oncology company with a unique biologic platform (ETB). They create smart toxins designed to penetrate cancer cells and destroy them from the inside. This chart compares their composite index to the sector, showing how their R&D platform outperforms the competition.
The AKIM Index for the overall market
Molecular Templates is a biotech company developing a new class of immunotoxins (ETBs) for cancer treatment. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this complex scientific platform.
